PABPN1 regulates mRNA alternative polyadenylation to inhibit bladder cancer progression.

PABPN1 regulates mRNA alternative polyadenylation to inhibit bladder cancer progression.
复制标题

DOI:
10.1186/s13578-023-00997-6
复制
发表时间:
2023-03-06
影响因子:
7.5
通讯作者:
Hou, Teng
Hou, Teng
中科院分区:
生物学2区
文献类型:
--
作者:
Chen, Liang;Dong, Wei;Zhou, Menghao;Yang, Chenlu;Xiong, Ming;Kazobinka, Gallina;Chen, Zhaohui;Xing, Yifei;Hou, Teng

文献摘要

参考文献

相似文献

约10%-20%的膀胱癌患者进展为肌肉侵袭性疾病,其潜在的关键分子事件尚未得到解决。在这里,我们发现多聚(A)结合蛋白核1(PABPN1),一种选择性多聚腺基化(APA)的通用因子,在BC中下调。PABPN1的过表达和敲除分别显著降低和增强BC的侵袭性。从机制上,我们提供的证据表明,PABPN1结合的多聚腺苷信号(PASS)的偏好取决于正则和非正则PASS之间的相对位置。PABPN1塑造汇聚在Wnt信号、细胞周期和脂质生物合成上的输入。总之,这些发现为PABPN1介导的APA调节如何促进BC的进展提供了洞察力,并表明针对PABPN1的药物靶向可能对BC患者具有治疗潜力。网上版载有补充材料,可在10.1186/s13578-023-00997-6查阅。
About 10–20% of patients with bladder cancer (BC) progress to muscle-invasive diseases, of which the underlying key molecular events have yet to be addressed. Here, we identified poly(A) binding protein nuclear 1 (PABPN1), a general factor of alternative polyadenylation (APA), was downregulated in BC. Overexpression and knockdown of PABPN1 significantly decreased and increased BC aggressiveness, respectively. Mechanistically, we provide evidence that the preference of PABPN1-bound polyadenylation signals (PASs) depends on the relative location between canonical and non-canonical PASs. PABPN1 shapes inputs converging on Wnt signaling, cell cycle, and lipid biosynthesis. Together, these findings provide insights into how PABPN1-mediated APA regulation contributes to BC progression, and suggest that pharmacological targeting PABPN1 might have therapeutic potential in patients with BC. The online version contains supplementary material available at 10.1186/s13578-023-00997-6.
DOI: 10.1093/nar/gkx892
发表时间: 2018-01-04
影响因子: 14.9
作者:
Feng X;Li L;Wagner EJ;Li W
通讯作者: Li W
DOI: 10.2147/dddt.s112113
发表时间: 2016
期刊: Drug design, development and therapy
影响因子: --
作者:
Smolensky D;Rathore K;Cekanova M
通讯作者: Cekanova M
NUDT21 通过 ANXA2 和 LIMK2 通过选择性多聚腺苷酸化促进膀胱癌进展
DOI: 10.7150/thno.36030
发表时间: 2019-01-01
期刊: THERANOSTICS
影响因子: 12.4
作者:
Xiong, Ming;Chen, Liang;Hou, Teng
通讯作者: Hou, Teng
DOI: 10.1111/cas.12472
发表时间: 2014-09
期刊: Cancer science
影响因子: 5.7
作者:
Ichinose J;Watanabe K;Sano A;Nagase T;Nakajima J;Fukayama M;Yatomi Y;Ohishi N;Takai D
通讯作者: Takai D
circNUDT21通过调节miR-16-1-3p/MDM2/p53轴促进膀胱癌进展
DOI: 10.1016/j.omtn.2021.08.032
发表时间: 2021-12-03
期刊: Molecular therapy. Nucleic acids
影响因子: --
作者:
Chen L;Li W;Li Z;Song Y;Zhao J;Chen Z;Kazobinka G;Li L;Xing Y;Hou T
通讯作者: Hou T